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Abstract
A 65-year-old man presented to his GP with right upper quadrant abdominal pain and weight loss. Abdominal ultrasound 
showed multiple gallstones and some ill-defined liver lesions. Computer tomography scan diagnosed a terminal ileal 
lesion causing cicatrisation of the terminal small bowel but does liver abnormality. The patient was worked up with 
serum gut hormone profile and magnetic resonance imaging of the liver which demonstrated multiple liver lesions and 
biochemical suspicion of neuroendocrine tumour (NET). The patient underwent a right hemicolectomy and excision/
ablation of 44 liver metastases. He made a good post-operative recovery and remains disease free after 18 months. We 
also present a brief literature review regarding advances in the management of metastatic NET.
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Introduction
Neuroendocrine tumours (NETs) represent a diverse group 
of neoplasms containing membrane-bound neurosecretory 
granules.[1] Clinical presentations depend on the staging 
of this disease and its functionality i.e., autonomous 
hormone secretion, which may lead to carcinoid syndrome 
characterised by nausea, vomiting, diarrhoea and 
abdominal cramps.[2] There has been a recent increase 
in the incidence of all gastrointestinal NETs, especially 
small bowel NETs (SB-NETs)[3] which may be due to an 
increased awareness and advances in diagnoses rather than 
a true rise in disease incidence. Modlin et al. reported SB-
NET to be the most common SB neoplasm with a three-
fold increase in incidence over the past three decades.[4]
The Surveillance, Epidemiology and End Results 
Programme showed that carcinoid syndrome typically 
present in sixth–seventh decades of life,[5] with an 
estimated prevalence of about 35/100,000 population.[2] 
The most common primary tumour sites are the SB and 
pancreas,[6] while the most common site of metastasis is 
the liver.[7]
We report the case of a patient diagnosed with primary 
SB-NET and liver metastases who then underwent surgery 
with curative intent. This case adds to the literature on 
the management of functioning primary SB-NET with 
distant metastases, in particular to the choice of imaging 
modalities and pushing the boundaries for surgical 
resection when feasible.
Case Report
A 65-year-old man was referred to hospital by his GP 
with a 4-day history of right upper-quadrant colicky 
abdominal pain, episodes of diarrhoea and unexplained 
3 kg weight loss over the past few months. His medical 
history consisted of hypertension, hypercholesterolaemia, 
bilateral inguinal hernia repair, sciatica, multiple basal cell 
carcinoma excision and diverticular disease.
Initial investigations showed abnormal liver function tests 
with mildly elevated alkaline phosphatase and alanine 
aminotransferase (142 U/L and 346 U/L, respectively). 
Abdominal ultrasound scan showed gallstones and a 
fatty liver with several solid and cystic lesions in both the 
lobes. To investigate this further, a computed tomography 
(CT) scan was organised which showed partially calcified 
lymphadenopathy in the mid-SB mesentery measuring 
1.8 cm with spiculations and a similarly calcified poorly 
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visualised mass in the adjacent SB measuring 1.8 cm 
which was consistent with mid-gut NET. CT scan did 
not identify any metastatic liver [Figure 1], lung or bony 
lesions. However, magnetic resonance imaging (MRI) of 
the liver [Figure 2] demonstrated >25 T2 hyperintense 
lesions in both the lobes of the liver. On dynamic contrast-
enhanced sequences, these lesions showed intense 
enhancement on arterial phase, complete rim enhancement 
on portal venous phase and complete washout on delayed 
phase, features consistent with hypervascular liver 
metastases. The patient also had radionuclide octreotide 
single-photon emission CT scan which showed a primary 
lesion in the SB, mesenteric nodal deposits and multiple 
liver metastases showing abnormal uptake. There was 
no evidence of overexpression of somatostatin receptors 
elsewhere. His chromogranins A and B were raised at 
214 pmol/L (<61) and 164 pmol/L (<151), respectively. 
Rest of the gut hormone profile was normal.
The patient was seen by a NET specialist and was started 
on somatostatin analogues. His case was also discussed 
at the combined hepatobiliary and NET multidisciplinary 
meetings, and it was decided to offer him surgery to 
remove the primary tumour and debulk the liver disease 
as much as possible.
An upper midline laparotomy with extension to 
the right subcostal region was performed. On the 
pre-operative ultrasound, it was felt that even MRI had 
underestimated the size and number of liver lesions. The 
patient underwent right hemicolectomy and regional 
lymphadenectomy, cholecystectomy and excision of 34 
liver lesions from both the lobes of the liver. Further, five 
superficial lesions were diathermy ablated and five deep 
seated lesions were radiofrequency ablated. A total of 44 
liver lesions were treated and no disease was left at the 
post-operative ultrasound scan.
The patient made a remarkable recovery and was able 
to return home 5 days after the surgery with long-term 
octreotide treatment. Follow-up scans were scheduled 
biannually in the first 24 months post-operation and 
every 9–12 months thereafter. The histopathology showed 
a well-differentiated grade 1 (Ki-67 immunostaining 
showed >1% staining) NET of the terminal ileum with 
multiple mesenteric and liver metastases (T3N1M1).
In the post-operative period, there was a significant 
reduction in the NET markers and improvement in 
the patient’s symptoms. The patient reported the 
disappearance of episodic facial flushing but did complain 
of minor diarrhoea with fatty stools. Faecal elastase levels 
were found to be low (163 µg E1/g stool), indicating mild-
to-moderate exocrine pancreatic insufficiency secondary 
to long-term octreotide use. This was addressed by an 
increase in the patient’s pancreatin (Creon) dose.
The patient was advised to remain on long-term octreotide 
in case there were smaller undetected metastases that 
Figure 1: Pre-operative computer tomography scan (late arterial 
phase). No liver lesions seen
Figure 2: Pre-operative magnetic resonance imaging (short TI 
inversion recovery sequence): multiple hyperintense metastases 
in both the lobes of the liver
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could not be resected and to relieve any residual functional 
symptoms of carcinoid syndrome. At 6-, 12- and 18-month 
follow-up, the patient is asymptomatic. Chest, abdomen 
and pelvic scans remain negative for recurrence, and 
chromogranin A and B levels remain normal at 35 and 
72 pmol/L, respectively.
Discussion
Surgical resection of SB-NET remains the treatment 
of choice when possible.[8] The survival rates improve 
further when the metastatic disease is also removed.[9] 
The treatment strategy has been outlined by the European 
NET Society and is recommended in patients with 
low morbidity and mortality, including the absence 
of extra-abdominal metastases, diffuse peritoneal 
carcinomatosis and right heart insufficiency.[10]
In this case, cytoreductive surgery (debulking) enabled 
resection of the primary tumour, liver metastases and 
lymph nodes. One study showed that aggressive intra-
abdominal debulking of such tumours resulted in a median 
survival of 139 months, compared to 69 months for those 
who did not undergo debulking.[11] Of those with liver 
involvement, liver-directed intervention prolonged a 
survival by 216 months compared to 48 months.[11]
Cytoreductive surgery is not without its potential 
complications; these commonly include post-operative 
infections, abscess formation, bile leak and hepatic 
failure. Parenchymal-sparing techniques such as ablation, 
enucleation and wedge resections, however, offer greater 
safety and efficacy than other surgical techniques.[12,13]
It is interesting to see that multiple liver lesions were 
not seen at the CT scan, and even the MRI of the 
liver underestimated the bulk of liver disease. To our 
knowledge, there is no study directly comparing the 
utility of CT and MRI in localising primary NET lesions 
and distant metastases, but it is appreciated by experts 
that MRI of the liver gives better information than CT 
scan. Multiple studies have compared the usefulness of a 
variety of imaging modalities (CT, MRI, SRS and PET), 
all of which showed reasonable sensitivity and specificity 
in localising primary lesions and distant metastases.[14-20]
In summary, this case has demonstrated the superiority 
of MRI in detecting liver metastases with the benefit of 
zero radiation to the patient and, in our opinion, is the 
investigation of choice. It is also important to recognise 
that NETs are slow-growing tumours and do not behave 
like adenocarcinomas. It is, therefore, entirely reasonable to 
be aggressive in the surgical resection for these patients as 
cytoreductive therapy significantly improves their prognosis.
Learning points
• NETs are rare and may present with trivial symptoms.
• MRI is superior to CT imaging in detecting NET liver 
metastases.
• Cytoreductive surgery is effective in managing 
metastatic disease.
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